News | Heart Valve Technology | November 10, 2016

First Patient Treated in U.S. Trial of NeoChord DS1000 System

RECHORD Trial will assess safety and effectiveness of off-pump, minimally invasive repair device for degenerative mitral regurgitation

NeoChord, RECHORD Trial, first patient, DS1000 System, degenerative mitral regurgitation, DMR

November 10, 2016 — NeoChord Inc. announced the first use of its DS1000 System in the United States as it enrolled the first patient in the RECHORD Trial.

The RECHORD Trial is a prospective, multicenter, randomized U.S. Food and Drug Administration (FDA) pivotal study intended to establish the safety and effectiveness of the DS1000 System as an alternative to standard surgical mitral valve repair. The study was approved to enroll up to 585 subjects at up to 20 U.S. centers. This study is the first trial of its kind to treat degenerative mitral regurgitation (DMR) patients that have ruptured or elongated chordae tendinae in a trans-apical, beating heart procedure.

David H. Adams, M.D., cardiac surgeon-in-chief, Mount Sinai Health System, and his team successfully treated the first patient in the RECHORD Trial at The Mount Sinai Hospital in New York, N.Y. Adams, national co-principal investigator of the trial, noted, “The success that we observed with our first patient in the trial is very promising and is indicative of the strong clinical results observed in Europe in appropriately selected patients with degenerative mitral valve regurgitation.”

“NeoChord’s technology has the potential to empower surgeons to intervene earlier in the disease process than previously possible and before significant ventricular changes occur,” said Co-Principal Investigator Michael A. Borger, M.D., Ph.D., professor and director, Cardiovascular Institute, New York Presbyterian Hospital/Columbia University Medical Center in New York, NY. “Clinical evidence that demonstrates the benefit of earlier intervention would truly transform the surgical treatment paradigm for patients suffering from DMR.”

In standard mitral valve repair procedures, patients are placed on cardiopulmonary bypass — the heart is arrested while the mitral valve is exposed and repaired. NeoChord’s DS 1000 System technology allows for a truly minimally invasive procedure via a transapical puncture on a beating heart without the need for cardio-pulmonary bypass or aortic cross-clamping. As a result, the invasiveness of the repair procedure is significantly reduced. With the NeoChord procedure, the surgeon uses real-time echocardiographic feedback in the operating room (OR) to precisely adjust the length of the newly placed chords and to reduce and/or eliminate mitral valve regurgitation, while the heart is beating and functioning.

The NeoChord DS1000 System is CE marked and approved for sale in Europe. It is an investigational device in the United States, limited by federal law to investigational use.

For more information:

Related Content

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init